source
- J&J to acquire Firefly Bio for $1 billion, boosting its KRAS-focused antibody-degrader programJohnson & Johnson announced it will purchase Firefly Bio, a preclinical biotech, for $1 billion in cash. Firefly Bio is developing degrader antibody conjugates that aim to target KRAS-driven cance…
- Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfrontIncyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion. The acquisition gives Incyte control of…